KVYO Form 144 Filed — 145,768 Series A Shares Scheduled for Sale
Rhea-AI Filing Summary
Klaviyo, Inc. filed a Form 144 reporting a proposed sale of 145,768 shares of its Series A common stock, with an aggregate market value of $4,839,497.60. The shares are scheduled for sale on 09/08/2025 on the NYSE. The filer acquired 1,983,585 shares on 09/20/2023 in pre-IPO transactions from Klaviyo, Inc., and indicates the purchase was paid with equity interests in the issuer. No securities of the issuer were reported sold by the filer in the past three months. The filing includes the required representation that the seller is not aware of undisclosed material adverse information about the company.
Positive
- Regulatory compliance: The filer provided required Rule 144 disclosure details, including broker, sale date, and acquisition history.
- No recent sales: The filing states there were no securities sold by the filer in the past three months.
Negative
- Insider sale disclosed: The filer plans to sell 145,768 shares valued at $4,839,497.60, which represents insider liquidity that investors may view negatively.
Insights
TL;DR Insider-originated pre-IPO shares worth about $4.84M are slated for sale; disclosure follows Rule 144 requirements.
The filing shows a planned resale of 145,768 Series A shares on the NYSE valued at $4,839,497.60. These shares were acquired in a pre-IPO transaction on 09/20/2023, when the filer received 1,983,585 shares. The notice indicates payment was made via equity interests in the issuer and that there were no reported sales in the prior three months. From an investor-impact perspective, this is a routine Rule 144 resale notice that provides transparency about insider liquidity but does not, by itself, change the company’s financials or operations.
TL;DR Form 144 is a standard regulatory disclosure of an insider sale; compliance reduces regulatory risk but signals insider liquidity.
The document reflects compliance with resale disclosure obligations under Rule 144: it specifies the class, broker (Barclays Capital Inc.), planned sale date, and acquisition details showing pre-IPO origin. The filer affirms lack of undisclosed material adverse information, which is a required representation. For governance review, the filing documents an insider exercising liquidity options; absent additional context on timing or volume relative to total holdings, it is a neutral governance event but merits monitoring if further insider sales occur.